Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BPM 31510 + Gemcitabine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BPM 31510 | BPM31510|BPM-31510 | BPM 31510 is a small molecule agent containing a formulation of co-enzyme Q10, thereby affecting metabolism via Warburg effect reversal and thus, potentially resulting in apoptotic activity of cancer cells (Cancer Res 2014;74(19 Suppl):Abstract nr 4321, PMID: 32807842). | ||
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02650804 | Phase II | BPM 31510 BPM 31510 + Gemcitabine | BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients | Completed | USA | GBR | 0 |